Healthcare
Relay Therapeutics, Inc.(RLAY)
Live Price
Offline$15.88
+2.06% today
1Y Change
+341.69%
Window
Jun 20, 2025 โ Jun 9, 2026
- Market Cap
- $2.27B
- Revenue Growth
- +53.4%
- EPS Growth
- +31.8%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 20, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Relay Therapeutics, Inc. (RLAY) is a Healthcare stock with a market cap of $2.27B and listed on NASDAQ. The stock last traded around $15.88 and up 341.7% across the available one-year price window (Jun 20, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of +53.4%, EPS growth of +31.8%, a dividend yield of 0.0%. What stands out right now is revenue +53.4%, EPS +31.8%, free cash flow +6.1% with operating margin -1971.5% and ROIC -50.5%. Valuation already assumes a fairly strong business story at price/sales 148.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RLAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+53.4% vs +7.6% peer median
Operating Margin
Below sector median
-1971.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +53.4% and EPS at +31.8%, with operating margin around -1971.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -0.7% | -1.8% | +19.9% |
2026 Feb 26, 2026 | +15.8% | +12.0% | +5.2% | +10.5% |
2025 Nov 6, 2025 | -10.3% | -7.4% | -1.2% | +17.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLAY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RLAY Max Drawdown
-28.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RLAY and SPY.
Company Overview
Relay Therapeutics, Inc.
NASDAQ Global Market
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Sanjiv K. Patel
- IPO Date
- Jul 16, 2020
- Employees
- 259
- Street Address
- 399 Binney Street
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 370 8837
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 148.0
- Price/Book
- 3.8
Growth
- Revenue
- +53.4%
- EPS
- +31.8%
- Free Cash Flow
- +6.1%
Profitability
- Gross Margin
- 91.2%
- Operating Margin
- -1971.5%
- Net Margin
- -1800.5%
- ROE
- -43.2%
- ROIC
- -50.5%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 22.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.